Literature DB >> 1355799

Effects of exposure to benzodiazepine during fetal life.

U Bergman1, F W Rosa, C Baum, B E Wiholm, G A Faich.   

Abstract

Dysmorphism and mental retardation have been reported in 7 Swedish children born of mothers who had taken high doses of benzodiazepines regularly during pregnancy. To explore this association further, we examined benzodiazepine use during pregnancy in 104,000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83. Fetal outcomes were assessed from the health claims profiles of their offspring, up to 6-9 years after delivery. 80 pregnant women had received 10 or more benzodiazepine prescriptions during the 4 years. Their records showed heavy general use of health care and frequent alcohol and substance abuse, and other disorders that could confound any effect of the benzodiazepines. For the 80 pregnancies, 3 intrauterine deaths were identified as well as 2 infants with congenital abnormalities whose curtailed records suggested neonatal death. Records of 64 surviving children could be linked to these 80 pregnancies whilst records for 11 apparent survivors could not be located. 6 of the 64 survivors had diagnoses consistent with teratogenic abnormalities. The high rate of teratogenicity after heavy maternal benzodiazepine use occurs with multiple alcohol and substance exposure and thus may not be due to benzodiazepine exposure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355799     DOI: 10.1016/0140-6736(92)92232-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  A comparison of behavioural effects of prenatally administered oxazepam in mice exposed to open-fields in the laboratory and the real world.

Authors:  M Fiore; G Dell'Omo; E Alleva; H P Lipp
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

3.  Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study.

Authors:  William V Bobo; Robert L Davis; Sengwee Toh; De-Kun Li; Susan E Andrade; T Craig Cheetham; Pamala Pawloski; Sascha Dublin; Simone Pinheiro; Tarek Hammad; Pamela E Scott; Richard A Epstein; Patrick G Arbogast; James A Morrow; Judith A Dudley; Jean M Lawrence; Lyndsay A Avalos; William O Cooper
Journal:  Paediatr Perinat Epidemiol       Date:  2012-11       Impact factor: 3.980

4.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

5.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

6.  Short-Term Oral Diazepam Treatment during Pregnancy : A Population-Based Teratological Case-Control Study.

Authors:  Andrew E Czeizel; Erika Erös; Magda Rockenbauer; Henrik T Sørensen; Jorn Olsen
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 7.  Pharmacologic interventions for pregnant women enrolled in alcohol treatment.

Authors:  Erica J Smith; Steve Lui; Mishka Terplan
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Use of psychotropic drugs during pregnancy. A report of the international co-operative drug use in pregnancy (DUP) study. Collaborative Group on Drug Use in Pregnancy (CGDUP).

Authors:  F Marchetti; M Romero; M Bonati; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.

Authors:  Konstantinos N Fountoulakis; Heinz Grunze; Eduard Vieta; Allan Young; Lakshmi Yatham; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.